

Special Issue

Protein- and Subunit-Based Vaccines

Message from the Guest Editors

Protein- or subunit-based vaccines comprise whole proteins or portions of them, such as epitopes, that have been specifically chosen for their capacity to stimulate an immune response. Traditional vaccines based on whole-pathogen have been effective in preventing many infectious diseases. However, traditional vaccines have some limitations regarding security issues as many of them need to be produced in high-level biosafety facilities, implying substantial manufacturing costs. As an alternative, protein- and subunit-based vaccines can be produced using recombinant expression systems, focusing only on the specific portion of the pathogen that triggers the immune response. They often need a substance or component that elicits a more potent humoral or cellular immune response. Different components have been used as adjuvants, and other approaches have been applied to deliver and present proteins and epitopes to the immune system. This Special Issue focuses on protein- and subunit-based vaccines, including preclinical and clinical studies, alternative delivery and display approaches, formulation optimization, and production strategies.

Guest Editors

Dr. Marco Palma

Institute for Globally Distributed Open Research and Education (IGDORE), Torrevieja, Spain

Prof. Dr. Jorge Benavide

Tecnologico de Monterrey, Institute for Obesity Research, Monterrey, Mexico

Deadline for manuscript submissions

closed (31 August 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/136213

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).